Market Overview

Pharmaceuticals and Healthcare Industry Report Q4 2012: Bangladesh, Estonia, Morocco & Indonesia

RnRMarketResearch.com adds Q4 2012 Reports on Pharmaceuticals and Healthcare market for Bangladesh, Estonia, Morocco & Indonesia to its store.

Dallas, Texas (PRWEB) November 21, 2012

In July 2012, it was reported that the prices of more than 1,200 pharmaceutical products have
increased by 20-100% in Bangladesh in the last few months. The authorities have reportedly
remained indifferent to the issue, which has resulted in price rises by the country's pharmaceutical companies at retail level. Drug manufacturers have attributed the price hikes primarily to the rise in international market prices of raw materials and a fall in the value of the currency.

Bangladesh Pharmaceuticals & Healthcare Report Q4 2012 Headline Expenditure Projections, Key Trends And Developments

1.    Pharmaceuticals: BDT111.10bn (US$1.50bn) in 2011 to BDT124.15bn (US$1.52bn) in 2012;
+11.7% in local currency terms and +1.1% in US dollar terms.
2.    Healthcare: BDT271.27bn (US$3.66bn) in 2011 to BDT304.45bn (US$3.72bn) in 2012;
+12.2% in local currency terms and +1.6% in US dollar terms.
3.    Medical devices: BDT12.91bn (US$174mn) in 2011 to BTD14.44bn (US$176mn) in 2012;
+11.8% in local currency terms and +1.2% in US dollar terms.

Buy your copy of Bangladesh Pharmaceuticals & Healthcare Report @ http://www.rnrmarketresearch.com/bangladesh-pharmaceuticals-and-healthcare-report-q4-2012-market-report.html

Estonia Pharmaceuticals & Healthcare Report Q4 2012 Headline Expenditure Projections, Key Trends And Developments

1.    Pharmaceuticals: EUR240mn (US$334mn) in 2011 to EUR253mn (US$322mn) in 2012; +5.6% in local currency terms and -3.5% in US dollar terms. US forecast unchanged from
Q312.
2.    Healthcare: EUR909mn (US$1.26bn) in 2011 to EUR945mn (US$1.20bn) in 2012; +3.9% in local currency terms and -5.1% in US dollar terms. Forecast slightly down from Q312 on
account of tightening fiscal conditions.
3.    Medical devices: EUR97mn (US$134mn) in 2011 to EUR101mn (US$128mn) in 2012; +4.2% in local currency terms and -4.8% in US dollar terms. Forecast slightly down from Q312 due to worsening macroeconomic conditions and reassessment of historical data.

The renovation of Haapsalu Neurological Rehabilitation Centre, a key rehabilitation centre in Estonia, started in May 2012, with a significant amount of support from the European Regional Development Fund. The EUR4mn (US$5.2mn) project, which is expected to be completed by 2014, includes the construction of an extra floor for the building to allow a research centre for neurological research studies.

Morocco Pharmaceuticals and Healthcare Report Q4 2012 Headline Expenditure Projections, Key Trends And Developments

1.    Pharmaceuticals: MAD10.10bn (US$1.25bn) in 2011 to MAD11.16bn (US$1.30bn) in 2012; +10.5% in local currency terms and +3.8% in US dollar terms. Forecast broadly unchanged
from Q312.
2.    Healthcare: MAD42.10bn (US$5.20bn) in 2011 to MAD46.9bn (US$5.44bn) in 2012; +11.3% in local currency terms and +4.6% in US dollar terms. Forecast broadly unchanged from
Q312.
3.    Medical devices: MAD2.19bn (US$270mn) in 2011 to MAD2.45bn (US$285mn) in 2012; +12.3% in local currency terms and +5.5% in US dollar terms. Forecast broadly unchanged
from Q312.

Buy your copy of Morocco Pharmaceuticals & Healthcare Report @ http://www.rnrmarketresearch.com/morocco-pharmaceuticals-and-healthcare-report-q4-2012-market-report.html

The full implementation of Morocco's subsidized health insurance scheme, RAMED, will help upgrade the healthcare sector and increase access. With higher demand for services and lower
medicine prices due to increased generic usage, the public and private sectors will see spending increase sharply. However, Morocco's public finances may become overstretched as the government attempts to support 8.5mn people on low incomes.

The European model of socialist healthcare is extremely expensive and difficult to administer efficiently. The government may have to lower its targets for RAMED healthcare coverage.
Morocco's pharmaceutical industry, which supplies approximately 70% of the domestic market, is highly competitive and has been commended for its high manufacturing standards. A number of multinationals operate local manufacturing plants and have selected Morocco as their North African headquarters. Sanofi, GlaxoSmithKline and Pfizer all operate local manufacturing plants, which are largely geared to meeting domestic demand.

Indonesia Pharmaceuticals & Healthcare Report Q4 2012 Headline Expenditure Projections, Key Trends And Developments

1.    Pharmaceuticals: IDR53,041bn (US$6.04bn) in 2011 to IDR58,706bn (US$6.33bn) in 2012;
+10.7% growth in local currency terms and +4.7% in US dollar terms. Local currency forecast
unchanged from previous quarter.
2.    Healthcare: IDR195,355bn (US$22.26bn) in 2011 to IDR223,410bn (US$24.09bn) in 2012;
+14.4% growth in local currency terms and +8.2% in US dollar terms. Local currency forecast
unchanged from previous quarter.
3.    Medical devices: IDR5,721bn (US$652mn) in 2011 to IDR6,290bn (US$678mn) in 2012;
+10.0% growth in local currency terms and +4.0% in US dollar terms. Local currency forecast
unchanged from previous quarter.

In August 2012, the Indonesian Ministry of Health withdrew the antiretroviral drug stavudine from the market, the director for direct contagious disease control, M. Subuh, has been reported
as saying. The ministry took the decision as the consumption of the drug may result in mediumor long-term dangerous side-effects, Subuh said. In a memo issued by Subuh, hospitals offering
antiretroviral (ARV) drugs have been asked to swap the drug, which has the scientific name d4T, with tenofovir disoproxil fumarate.

Contact sales(at)rnrmarketresearch(dot)com for further information.

About Us:
RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online database of market research reports offers in-depth analysis of over 5000 market segments.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012-pharmaceuticals-and/healthcare-report/prweb10158909.htm

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free